Hypertension in the kidney transplant recipient

Transplantation Reviews

Volumn 24, Issue 3, 2010, Pages 105-120

  Wadei, Hani M ^a   Textor, Stephen C ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLOSPORIN; DIHYDROPYRIDINE; DILTIAZEM; ENALAPRIL; IMMUNOSUPPRESSIVE AGENT; LABETALOL; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; RAMIPRIL; SPIRONOLACTONE; TACROLIMUS; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR RISK; COMORBIDITY; CONSTIPATION; DIZZINESS; EDEMA; ELECTROLYTE DISTURBANCE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; METABOLIC ACIDOSIS; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POSTTRANSPLANT HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT PLANNING; UREMIA; WHITE COAT HYPERTENSION; XEROSTOMIA; BLOOD PRESSURE; DRUG INTERACTION; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG INTERACTIONS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 77954426850     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.02.001     Document Type: Review

References (152)

1. Mange K.C., Cizman B., Joffe M., Feldman H.I. Arterial hypertension and renal allograft survival. JAMA 2000, 283:633-638.
2. Mange K.C., Feldman H.I., Joffe M.M., Fa K., Bloom R.D. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol 2004, 15:187-193.
3. Opelz G., Wujciak T., Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53:217-222.
4. Aakhus S., Dahl K., Wideroe T.E. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004, 18:596-604.
5. Rigatto C., Parfrey P., Foley R., Negrijn C., Tribula C., Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002, 13:1084-1090.
6. Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000, 11:1735-1743.
7. Adams H.P., Dawson G., Coffman T.J., Corry R.J. Stroke in renal transplant recipients. Arch Neurol 1986, 43:113-115.
8. Oliveras A., Roquer J., Puig J.M., et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant 2003, 17:1-8.
9. Kasiske B.L., Anjum S., Shah R., et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004, 43:1071-1081.
10. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006, 82:603-611.
11. Cosio F.G., Dillon J.J., Falkenhain M.E., et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995, 47:1136-1141.
12. Cosio F.G., Falkenhain M.E., Pesavento T.E., et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997, 29:419-427.
13. Campistol J.M., Romero R., Paul J., Gutierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004, 19(Suppl 3):iii62-iii66.
14. Ducloux D., Motte G., Kribs M., et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002, 57:409-413.
15. Perez Fontan M., Rodriguez-Carmona A., Garcia Falcon T., Fernandez Rivera C., Valdes F. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999, 33:21-28.
16. Pickering T.G., Shimbo D., Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006, 354:2368-2374.
17. Wadei H.M., Amer H., Taler S.J., et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol 2007, 18:1607-1615.
18. Paoletti E., Gherzi M., Amidone M., Massarino F., Cannella G. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009, 87:1864-1869.
19. Haydar A.A., Covic A., Jayawardene S., et al. Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation 2004, 77:849-853.
20. Bangash F., Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2009, 4:656-664.
21. Bobrie G., Chatellier G., Genes N., et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004, 291:1342-1349.
22. Bobrie G., Clerson P., Menard J., Postel-Vinay N., Chatellier G., Plouin P.F. Masked hypertension: a systematic review. J Hypertens 2008, 26:1715-1725.
23. Clement D.L., De Buyzere M.L., De Bacquer D.A., et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003, 348:2407-2415.
24. Shimada K., Kawamoto A., Matsubayashi K., Nishinaga M., Kimura S., Ozawa T. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 1992, 10:875-878.
25. Verdecchia P., Porcellati C., Schillaci G., et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994, 24:793-801.
26. Lurbe E., Redon J., Kesani A., et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805.
27. Agarwal R., Andersen M.J. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006, 69:1175-1180.
28. Davidson M.B., Hix J.K., Vidt D.G., Brotman D.J. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 2006, 166:846-852.
29. Khot U.N., Binkley P.F., Haas G.J., Starling R.C. Prospective study of the circadian pattern of blood pressure after heart transplantation. J Heart Lung Transplant 1996, 15:350-359.
30. Taler S.J., Textor S.C., Canzanello V.J., Wilson D.J., Wiesner R.H., Krom R.A. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. Am J Hypertens 1995, 8:598-605.
31. Agarwal R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Current opinion in nephrology and hypertension 2009.
32. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1-S290.
33. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant 2002, 17(Suppl 4):1-67.
34. Special issue: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S155.
35. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
36. Bahous S.A., Stephan A., Blacher J., Safar M.E. Aortic stiffness, living donors, and renal transplantation. Hypertension 2006, 47:216-221.
37. Delahousse M., Chaignon M., Mesnard L., et al. Aortic stiffness of kidney transplant recipients correlates with donor age. J Am Soc Nephrol 2008, 19:798-805.
38. Textor S.C., Schwartz L., Wilson D.J., et al. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension 1994, 23:I220-I224.
39. Kone B.C., Whelton A., Santos G., Saral R., Watson A.J. Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med 1988, 69:985-995.
40. Textor S.C., Wiesner R., Wilson D.J., et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993, 55:1332-1339.
41. Thompson M.E., Shapiro A.P., Johnsen A.M., et al. The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. Int J Cardiol 1986, 11:219-229.
42. Textor S.C., Canzanello V.J., Taler S.J., et al. Cyclosporine-induced hypertension after transplantation. Mayo Clinic Proc 1994, 69:1182-1193.
43. Kurtz A., Della Bruna R., Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988, 33:947-953.
44. Lassila M. Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. Curr Drug Metab 2002, 3:61-71.
45. Mason J., Muller-Schweinitzer E., Dupont M., et al. Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 1991, 32:S28-S32.
46. Iijima K., Hamahira K., Kobayashi A., Nakamura H., Yoshikawa N. Immunohistochemical analysis of renin activity in chronic cyclosporine nephropathy in childhood nephrotic syndrome. J Am Soc Nephrol 2000, 11:2265-2271.
47. Tufro-McReddie A., Gomez R.A., Norling L.L., Omar A.A., Moore L.C., Kaskel F.J. Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney. Kidney international 1993, 43:615-622.
48. Textor S.C., Wilson D.J., Lerman A., et al. Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. Transplantation 1992, 54:74-80.
49. Textor S.C., Burnett J.C., Romero J.C., et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995, 47:1426-1433.
50. Takeda Y., Miyamori I., Wu P., Yoneda T., Furukawa K., Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995, 26:932-936.
51. Siedlecki A., Anderson J.R., Jin X., Garbow J.R., Lupu T.S., Muslin A.J. RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity. Am J Transplant 2009, 9999.
52. Hausberg M., Lang D., Levers A., et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. J Hypertens 2006, 24:957-964.
53. Ciresi D.L., Lloyd M.A., Sandberg S.M., Heublein D.M., Edwards B.S. The sodium retaining effects of cyclosporine. Kidney Int 1992, 41:1599-1605.
54. Sturrock N.D., Lang C.C., MacFarlane L.J., et al. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995, 13:667-673.
55. Canzanello V.J., Textor S.C., Taler S.J., et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. J Am Soc Nephrol 1995, 5:1910-1917.
56. Curtis J.J., Luke R.G., Jones P., Diethelm A.G. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988, 85:134-138.
57. Sturrock N.D., Lang C.C., Struthers A.D. Cyclosporin-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertens 1993, 11:1209-1216.
58. Taler S.J., Textor S.C., Canzanello V.J., et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996, 62:1588-1592.
59. Goodwin J.E., Zhang J., Geller D.S. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol 2008, 19:1291-1299.
60. Grunfeld J.P., Kleinknecht D., Moreau J.F., et al. Permanent hypertension after renal homotransplantation in man. Clin Sci Mol Med 1975, 48:391-403.
61. Audard V., Matignon M., Hemery F., et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant 2006, 6:95-99.
62. Voiculescu A., Schmitz M., Hollenbeck M., et al. Management of arterial stenosis affecting kidney graft perfusion: a single-centre study in 53 patients. Am J Transplant 2005, 5:1731-1738.
63. Halimi J.-M., Al-Najjar A., Buchler M., et al. Transplant renal artery stenosis: potential role of ischemia/reperfusion injury and long-term outcome following angioplasty. The Journal of Urology 1999, 161:28-32.
64. Bruno S., Remuzzi G., Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol 2004, 15:134-141.
65. Wong W., Fynn S.P., Higgins R.M., et al. Transplant renal artery stenosis in 77 patients-does it have an immunological cause?. Transplantation 1996, 61:215-219.
66. Hagen G., Wadstrãm J., Magnusson M., Magnusson A. Outcome after percutaneous transluminal angioplasty of arterial stenosis in renal transplant patients. Acta Radiol 2009, 50:270-275.
67. Henning B.F., Kuchlbauer S., Boger C.A., et al. Percutaneous transluminal angioplasty as first-line treatment of transplant renal artery stenosis. Clin Nephrol 2009, 71:543-549.
68. Zhang Z.F., Liang H.M., Feng G.S., Zheng C.S., Wu H.P., Zhou G.F. Interventional treatment of transplanted renal artery stenosis. Journal of Interventional Radiology 2008, 17:623-626.
69. Huysmans F.T., Hoitsma A.J., Koene R.A. Factors determining the prevalence of hypertension after renal transplantation. Nephrol Dial Transplant 1987, 2:34-38.
70. Hausberg M., Kosch M., Harmelink P., et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106:1974-1979.
71. Curtis J.J., Luke R.G., Diethelm A.G., Whelchel J.D., Jones P. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985, 2:739-742.
72. Shoma A.M., Eraky I., El-Kappany H.A. Pretransplant native nephrectomy in patients with end-stage renal failure: assessment of the role of laparoscopy. Urology 2003, 61:915-920.
73. Sanjeevan K.V., Bhat H.S., Sudhindran S. Laparoscopic simultaneous bilateral pretransplant nephrectomy for uncontrolled hypertension. Transplant Proc 2004, 36:2011-2012.
74. Bales G.T., Fellner S.K., Chodak G.W., Rukstalis D.B. Laparoscopic bilateral nephrectomy for renin-mediated hypertension. Urology 1994, 43:874-877.
75. Fornara P., Doehn C., Fricke L., Durek C., Thyssen G., Jocham D. Laparoscopic bilateral nephrectomy: results in 11 renal transplant patients. J Urol 1997, 157:445-449.
76. Opelz G., Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005, 5:2725-2731.
77. Meier-Kriesche H.U., Li S., Gruessner R.W., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006, 6:1111-1131.
78. Hricik D.E., Lautman J., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992, 53:1232-1235.
79. Vanrenterghem Y., Lebranchu Y., Hene R., Oppenheimer F., Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000, 70:1352-1359.
80. Ahsan N., Hricik D., Matas A., et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999, 68:1865-1874.
81. Hricik D.E., Knauss T.C., Bodziak K.A., et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003, 76:938-942.
82. Sarwal M.M., Vidhun J.R., Alexander S.R., Satterwhite T., Millan M., Salvatierra O. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003, 76:1331-1339.
83. Hocker B., Weber L.T., Feneberg R., et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009, 87:934-941.
84. Woodle E.S.M.D., First M.R.M.D., Pirsch J.M.D., et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008, 248:564-577.
85. Sivaraman P., Nussbaumer G., Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 2001, 37:1162-1169.
86. Ronald P.P., Baris A., Ronald M.F. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006, 20:10-18.
87. Pelletier R.P., Akin B., Ferguson R.M. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006, 20:10-18.
88. Johnson R.W., Kreis H., Oberbauer R., Brattstrom C., Claesson K., Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001, 72:777-786.
89. Schnuelle P., van der Heide J.H., Tegzess A., et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002, 13:536-543.
90. Hueso M., Bover J., Seron D., et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998, 66:1727-1731.
91. Waichi W., Nina T.-R., Francis L.D., et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant 2004, 18:341-348.
92. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353:770-781.
93. Ekberg H., Grinyo J., Nashan B., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007, 7:560-570.
94. Copley J.B., Staffeld C., Lindberg J., et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. Transplant Proc 1998, 30:1254-1256.
95. Ligtenberg G., Hene R.J., Blankestijn P.J., Koomans H.A. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001, 12:368-373.
96. Vincenti F., Jensik S.C., Filo R.S., Miller J., Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002, 73:775-782.
97. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002, 359:741-746.
98. Premasathian N.C., Muehrer R., Brazy P.C., Pirsch J.D., Becker B.N. Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens 2004, 18:871-877.
99. Martinez-Castelao A., Hueso M., Sanz V., Rejas J., Alsina J., Grinyo J.M. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl 1998, 68:S130-S134.
100. Ruggenenti P., Perico N., Mosconi L., et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993, 43:706-711.
101. Inigo P., Campistol J.M., Lario S., et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-{beta}1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001, 12:822-827.
102. Madsen J.K., Sorensen S.S., Hansen H.E., Pedersen E.B. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 1998, 13:2327-2334.
103. Birx D.L., Berger M., Fleisher T.A. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984, 133:2904-2909.
104. Boom H., Mallat M.J., de Fijter J.W., Paul L.C., Bruijn J.A., van Es L.A. Calcium levels as a risk factor for delayed graft function. Transplantation 2004, 77:868-873.
105. Palmer B.F., Dawidson I., Sagalowsky A., Sandor Z., Lu C.Y. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991, 52:640-645.
106. Chanard J., Toupance O., Lavaud S., Hurault de Ligny B., Bernaud C., Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003, 18:2147-2153.
107. Midtvedt K., Ihlen H., Hartmann A., et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001, 72:107-111.
108. Kuypers D.R., Neumayer H.H., Fritsche L., Budde K., Rodicio J.L., Vanrenterghem Y. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004, 78:1204-1211.
109. van Riemsdijk I.C., Mulder P.G., de Fijter J.W., et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000, 70:122-126.
110. Cross N.B., Webster A.C., Masson P., O'Connell P.J., Craig J.C. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009, 88:7-18.
111. Ruggenenti P., Perna A., Benini R., Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998, 9:2096-2101.
112. Amuchastegui S.C., Azzollini N., Mister M., Pezzotta A., Perico N., Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998, 9:1948-1955.
113. Jones T.E., Morris R.G. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002, 41:381-388.
114. Schrama Y.C., Koomans H.A. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. J Hypertens Suppl 1998, 16:S33-S38.
115. Curtis J.J., Laskow D.A., Jones P.A., Julian B.A., Gaston R.S., Luke R.G. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993, 3:1570-1574.
116. Gaston R.S., Kasiske B.L., Fieberg A.M., et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009, 9:1811-1815.
117. Thilly N., Bayat S., Alla F., Kessler M., Briancon S., Frimat L. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation. Clin Transplant 2008, 22:439-446.
118. Midtvedt K., Hartmann A., Foss A., et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001, 72:1787-1792.
119. Suwelack B., Kobelt V., Erfmann M., et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003, 16:313-320.
120. Hausberg M., Barenbrock M., Hohage H., Muller S., Heidenreich S., Rahn K.H. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999, 33:862-868.
121. Formica R.N., Friedman A.L., Lorber M.I., Smith J.D., Eisen T., Bia M.J. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006, 21:1389-1394.
122. Hiremath S., Fergusson D., Doucette S., Mulay A.V., Knoll G.A. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007, 7:2350-2360.
123. Omoto K., Tanabe K., Tokumoto T., Shimmura H., Ishida H., Toma H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 2003, 76:1170-1174.
124. Amer H., Fidler M.E., Myslak M., et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007, 7:2748-2756.
125. Roodnat J.I., Mulder P.G., Rischen-Vos J., et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001, 72:438-444.
126. Lorenz M., Billensteiner E., Bodingbauer M., Oberbauer R., Horl W.H., Haas M. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004, 43:1065-1070.
127. Heinze G., Collins S., Benedict M.A., et al. The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 2006, 82:1441-1448.
128. Heinze G., Mitterbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889-899.
129. Opelz G., Zeier M., Laux G., Morath C., Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006, 17:3257-3262.
130. Pazik J., Ostrowska J., Lewandowski Z., et al. Renin-angiotensin-aldosterone system inhibitors and statins prolong graft survival in post-transplant glomerulonephritis. Ann Transplant 2008, 13:41-45.
131. Artz M.A., Hilbrands L.B., Borm G., Assmann K.J., Wetzels J.F. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004, 19:2852-2857.
132. Campistol J.M., Inigo P., Jimenez W., et al. Losartan decreases plasma levels of TGF-[bgr]1 in transplant patients with chronic allograft nephropathy. Kidney international 1999, 56:714-719.
133. Mas V.R., Alvarellos T., Maluf D.G., et al. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy. Transpl Int 2004, 17:540-544.
134. Paoletti E., Cassottana P., Amidone M., Gherzi M., Rolla D., Cannella G. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis 2007, 50:133-142.
135. Knoll G.A., Cantarovitch M., Cole E., et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation-study design. Nephrol Dial Transplant 2008, 23:354-358.
136. Mitterbauer C., Heinze G., Kainz A., Kramar R., Horl W.H., Oberbauer R. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 2008, 23:1742-1746.
137. Stigant C.E., Cohen J., Vivera M., Zaltzman J.S. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000, 35:58-63.
138. Alessandra G., Andrea S., Giacomo Z., et al. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. Liver Transpl 2008, 14:1020-1028.
139. Huysmans F.T., van Heusden F.H., Wetzels J.F., Hoitsma A.J., Koene R.A. Antihypertensive effect of beta blockade in renal transplant recipients with or without host kidneys. Transplantation 1988, 46:234-237.
140. Bell D.S., Bakris G.L., McGill J.B. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab 2009, 11:234-238.
141. Roland M., Gatault P., Al-Najjar A., et al. Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2008, 8:1719-1728.
142. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L., The Atherosclerosis Risk in Communities S. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000, 342:905-912.
143. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Inter-American Society of Hypertension. Hypertension 2009.
144. Gross E., Rothstein M., Dombek S., Juknis H.I. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005, 46:94-101.
145. Lopes R., Lourenco P., Mascarenhas J., Azevedo A., Bettencourt P. Spironolactone therapy in heart failure patients with chronic kidney disease. Clin Cardiol 2009, 32:597.
146. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
147. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
148. Papadimitriou M., Vyzantiadis A., Milionis A., Memmos D., Metaxas P. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst 1983, 1:197-205.
149. Waanders F., Rienstra H., Boer M.W., et al. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol 2009, 296:F1072-F1079.
150. Feria I., Pichardo I., Juarez P., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney international 2003, 63:43-52.
151. Perez-Rojas J., Blanco J.A., Cruz C., et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007, 292:F131-F139.
152. Perez-Rojas J.M., Derive S., Blanco J.A., et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005, 289:F1020-F1030.